Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, 128 44 Prague 2, Czech Republic.
Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, 128 44 Prague 2, Czech Republic; Institute of Organic Chemistry and Biochemistry of the CAS, Flemingovo náměstí 542/2, 166 10, Praha 5, Czech Republic.
Virus Res. 2023 Jan 15;324:199031. doi: 10.1016/j.virusres.2022.199031. Epub 2022 Dec 29.
BK virus (BKPyV) is a causative agent of BKPyV-associated nephropathy and graft rejections in kidney transplant patients. It establishes persistent infection in the kidneys, which can lead to reactivation in an immunosuppressed state or transmission to kidney recipients. Complications in the case of donor-derived infections can be caused by differences between the four known BKPyV subtypes, as prior infection with one subtype does not guarantee protection against de novo infection with other subtypes. The recipient and donor pretransplant serotyping is not routinely performed since simple ELISA tests employing antigens derived from the major viral capsid protein 1 (VP1) are hindered by the high cross-reactivity of anti-VP1 antibodies against all subtypes. Identifying subtype-specific epitopes in VP1 could lead to the design of specific antigens and the improvement of serodiagnostics for kidney transplantation. We aimed to study the surface residues responsible for the interactions with the subtype-specific antibodies by focusing on the DE and EF loops of VP1, which have only a small number of distinct amino acid differences between the most common subtypes, BKPyV-I and BKPyV-IV. We designed two mutant virus-like particles (VLPs): we introduced BKPyV-I characteristic amino acid residues (either H139N in the DE loop or D175E and I178V changes in the EF loop) into the base sequence of a BKPyV-IV VP1. This way, we created BKPyV-IV mutant VLPs with the sequence of either the BKPyV-I DE loop or the BKPyV-I EF loop. These mutants were then used as competing antigens in an antigen competition assay with a panel of patient sera, and changes in antibody reactivity were assessed by ELISA. We found that the changes introduced into the BKPyV-IV VP1 EF loop restrict antibody recognition in most samples and that converting the BKPyV-IV DE loop into its BKPyV-I equivalent attracts anti-VP1 BKPyV-I antibodies. Although our results did not lead to the discovery of a subtype-specific epitope on the VP1, they suggested that the arrangement of the EF loop in VP1 might dictate the mode of interaction between virus and anti-VP1 antibodies in general and that the interactions between the antibodies and the viral capsid might be very complex. Consequently, an antigen competition assay as an assay to distinguish between BKPyV serotypes might prove difficult to interpret.
BK 病毒(BKPyV)是导致肾移植患者 BKPyV 相关性肾病和移植物排斥的病原体。它在肾脏中建立持续性感染,这可能导致在免疫抑制状态下重新激活或传播到肾接受者。供体来源感染的并发症可能是由四个已知的 BKPyV 亚型之间的差异引起的,因为先前感染一种亚型并不能保证对其他亚型的新发感染提供保护。由于使用源自主要病毒衣壳蛋白 1(VP1)的抗原的简单 ELISA 测试受到针对所有亚型的抗-VP1 抗体的高度交叉反应性的阻碍,因此不在移植前对供体和受体进行血清分型通常不进行。鉴定 VP1 中的亚型特异性表位可以导致针对特定抗原的设计,并改善肾移植的血清诊断。我们旨在通过专注于 VP1 的 DE 和 EF 环来研究负责与亚型特异性抗体相互作用的表面残基,VP1 的 DE 和 EF 环在最常见的亚型 BKPyV-I 和 BKPyV-IV 之间只有少数独特的氨基酸差异。我们设计了两种突变病毒样颗粒(VLPs):我们将 BKPyV-I 特征性氨基酸残基(DE 环中的 H139N 或 EF 环中的 D175E 和 I178V 变化)引入 BKPyV-IV VP1 的基础序列中。这样,我们用 BKPyV-I DE 环或 BKPyV-I EF 环的序列创建了具有 BKPyV-IV VP1 序列的 BKPyV-IV 突变 VLPs。然后,将这些突变体用作抗原竞争测定中与一组患者血清的竞争抗原,并通过 ELISA 评估抗体反应性的变化。我们发现,引入 BKPyV-IV VP1 EF 环中的变化限制了大多数样本中的抗体识别,而将 BKPyV-IV DE 环转化为其 BKPyV-I 等效物则吸引了抗-VP1 BKPyV-I 抗体。尽管我们的结果没有发现 VP1 上的亚型特异性表位,但它们表明 VP1 中 EF 环的排列可能决定病毒与抗-VP1 抗体之间的相互作用模式,并且抗体与病毒衣壳之间的相互作用可能非常复杂。因此,抗原竞争测定作为区分 BKPyV 血清型的测定可能难以解释。